{{short description|Aryl amine}} {{DISPLAYTITLE:''o''-Toluidine}} {{chembox | Name = ''o''-Toluidine | ImageFileL1 = O-Toluidin.svg | ImageFileR1 = O-Toluidine-3D-balls.png | ImageSize = 150px | PIN = 2-Methylaniline<ref name=iupac2013>{{cite book | title = Nomenclature of Organic Chemistry: IUPAC Recommendations and Preferred Names 2013 (Blue Book) | publisher = The Royal Society of Chemistry | date = 2014 | location = Cambridge | page = 669 | doi = 10.1039/9781849733069-FP001 | isbn = 978-0-85404-182-4 | quote = The names 'toluidine', 'anisidine', and 'phenetidine' for which ''o''-, ''m''-, and ''p''- have been used to distinguish isomers, and 'xylidine' for which numerical locants, such as 2,3-, have been used, are no longer recommended, nor are the corresponding prefixes 'toluidine', 'anisidino', 'phenetidine', and 'xylidino'.}}</ref> | OtherNames = ''o''-Methylaniline<br />''o''-Toluidine<br />1-Amino-2-methylbenzene<br />2-Aminotoluene, 2-Toluamine | Section1 = {{Chembox Identifiers | CASNo_Ref = {{cascite|correct|CAS}} | CASNo = 95-53-4 | ChEBI_Ref = {{ebicite|correct|EBI}} | ChEBI = 66892 | ChEMBL_Ref = {{ebicite|correct|EBI}} | ChEMBL = 1381 | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID = 13854136 | EC_number = 202-429-0 | PubChem = 7242 | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = C14403 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = B635MZ0ZLU | UNNumber = 1708 (O-TOLUIDINE) | StdInChI=1S/C7H9N/c1-6-4-2-3-5-7(6)8/h2-5H,8H2,1H3 | StdInChIKey = RNVCVTLRINQCPJ-UHFFFAOYSA-N | SMILES = CC1=CC=CC=C1N }} | Section2 = {{Chembox Properties | C=7|H=9|N=1 | Appearance = Colorless liquid | Odor = Aromatic, aniline-like odor | Density = 1.004 g/cm<sup>3</sup> | Solubility = 0.19 g/100 ml at 20&nbsp;°C | MeltingPtC = -23.68 | BoilingPtC = 200 to 202 | VaporPressure = 0.307531 mmHg (25&nbsp;°C) | RefractIndex = 1.56987 | Viscosity = 4.4335 (20 °C) }} | Section7 = {{Chembox Hazards | MainHazards= Flammable, moderately toxic | GHSPictograms = {{GHS02}}{{GHS06}}{{GHS07}}{{GHS08}}{{GHS09}} | GHSSignalWord = Danger | HPhrases = {{H-phrases|301|302|319|331|350|400}} | PPhrases = {{P-phrases|201|202|261|264|270|271|273|280|281|301+310|304+340|305+351+338|308+313|311|321|330|337+313|391|403+233|405|501}} | ExternalSDS = | NFPA-H = 3 | NFPA-F = 2 | NFPA-R = 0 | FlashPtC = 85 | AutoignitionPtC = 481.67 | LD50 = 900 mg/kg (rat, oral)<br/>323 mg/kg (rabbit, oral) }} | Section8 = {{Chembox Related | OtherCompounds = Toluidine }} }}

'''''o''-Toluidine''' ('''''ortho''-toluidine''') is an organic compound with the chemical formula CH<sub>3</sub>C<sub>6</sub>H<sub>4</sub>NH<sub>2</sub>. It is the most important of the three isomeric toluidines. It is a colorless liquid although commercial samples are often yellowish. It is a precursor to the herbicides metolachlor and acetochlor.<ref name=Ullmann>{{Ullmann|first=Joseph S. |last=Bowers |title=Toluidines |doi=10.1002/14356007.a27_159}}</ref>

==Synthesis and reactions== ''o''-Toluidine is produced industrially by nitration of toluene to give a mixture of nitrotoluenes, favoring the ortho isomer. This mixture is separated by distillation. 2-Nitrotoluene is hydrogenated to give o-toluidine.<ref name=Ullmann/>

The conversion of ''o''-toluidine to the diazonium salt gives access to the 2-bromo, 2-cyano-, and 2-chlorotoluene derivatives.<ref>{{cite journal|title=o-Tolunitrile and p-Tolunitrile|author=H. T. Clarke |author2=R. R. Read |journal=Org. Synth.|year=1925|volume=4|page=69 |doi=10.15227/orgsyn.004.0069}}</ref> <ref>{{cite journal|title=o-Bromotoluene |author=L. A. Bigelow |journal=Org. Synth.|year=1929|volume=9|page=22 |doi=10.15227/orgsyn.009.0022}}</ref> <ref>{{cite journal|title=o-Chlorotoluene and p-Chlorotoluene |author=C. S. Marvel |author2=S. M. McElvain |journal=Org. Synth.|year=1923|volume=3|page=33 |doi=10.15227/orgsyn.003.0033}}</ref> N-acetylation is also demonstrated.<ref>{{cite journal|title=Indazole|author=Rolf Huisgen |author2=Klaus Bast |journal=Org. Synth.|year=1962|volume=42|page=69|doi=10.15227/orgsyn.042.0069}}</ref>

==Safety== The LD50 (oral, rats) is 670 mg/kg.<ref name=Ullmann/>

===Binding of hemoglobin=== ''o''-Nitrosotoluene, a metabolite of ''o''-toluidine, converts hemoglobin to methemoglobin, resulting in methemoglobinemia.<ref>{{cite book|publisher=U.S. Department of Health and Human Services |title=Hazardous Substances Data Bank (HSDB, online database) |series=National Toxicology Information Program |location=National Library of Medicine, Bethesda, MD |date=1997}}</ref><ref>{{cite book|editor1-first=G. D. |editor1-last=Clayton |editor2-first=F. E. |editor2-last=Clayton |title=Patty's Industrial Hygiene and Toxicology. |volume=2A |edition=3rd rev. |publisher=John Wiley & Sons |location=New York |date=1981}}</ref>{{ISBN missing}}<ref>{{cite journal|last1=Birnier |first1=G. |last2=Neumann |first2=H. |date=1988 |title=Biomonitoring of aromatic amines. II: Haemoglobin binding of some monocyclic aromatic amines |journal=Arch. Toxicol. |volume=62 |issue=2–3 |pages=110–115|doi=10.1007/BF00570128 |pmid=3196145 |bibcode=1988ArTox..62..110B |s2cid=33391149 }}</ref>

''o''-Nitrosotoluene is suspected of causing bladder cancer in rats.<ref name=englishetal/><ref>{{cite book|last=Eyer |first=P. |title=Toxicology in the Use, Misuse, and Abuse of Food, Drugs, and Chemicals |chapter=The Red Cell as a Sensitive Target for Activated Toxic Arylamines |date=1983 |volume=6 |pages=3–12|doi=10.1007/978-3-642-69083-9_1 |series=Archives of Toxicology, Supplement |pmid=6578736 |isbn=978-3-540-12392-7}}</ref><ref>{{cite journal|last1=Hecht |first1=S. S. |last2=El-Bayoumy |first2=K. |last3=Rivenson |first3=A. |last4=Fiala |first4=E. |date=1983 |title=Bioassay for carcinogenicity of 1,2-dimethyl-4-nitrosobiphenyl, ''o''-nitrosotoluene, nitrosobenzene and the corresponding amines in Syrian golden hamsters |journal=Cancer Lett. |volume=20 |issue=3 |pages=349–354 |doi=10.1016/0304-3835(83)90034-4|pmid=6627231}}</ref> Nitrosotoluene exposure has been researched in a number of different degrees in animals.<ref name=npsolvents/><ref name=roc/><ref>{{cite book|first=N. |last=Gregg |display-authors=etal |title=o-Toluidine |publisher=World Health Organization |date=1998 |pages=5–22 |isbn=92-4-153007-3}} (NLM classification: QV 235.)</ref><ref>{{cite journal|first1=G. F. |last1=Rubino |first2=G. |last2=Scansetti |first3=G. |last3=Piolatto |first4=E. |last4=Fira |title=The carcinogenic effect of aromatic amines: An epidemiological study on the role of ''o''-toluidine and 4,4′-methylenebis(2-methylaniline) in inducing bladder cancer in man |date=1982 |journal=Env. Res. |volume=27 |issue=2 |pages=241–254 |doi=10.1016/0013-9351(82)90079-2|pmid=7084156 |bibcode=1982ER.....27..241R }}</ref>

===Carcinogenicity=== In the U.S., ''o''-toluidine was first listed in the Third Annual Report on Carcinogens as 'reasonably anticipated to be a human carcinogen' in 1983, based on sufficient evidence from studies in experimental animals. The Report on Carcinogens (RoC) is a U.S. congressionally-mandated, science-based public health report that identifies agents, substances, mixtures, or exposures in the environment that pose a hazard to people residing in the United States<ref>{{cite book|last=Burwell |first=S. M. |date=2014 |title=Report on Carcinogens |edition=13th}}</ref> Since then, other cancer related studies have been published and the listing of ''o''-toluidine was changed to 'known to be a human carcinogen'. ''o''-toluidine was especially linked to bladder cancer. This was done 31 years later in the [https://web.archive.org/web/20141004142519/http://ntp.niehs.nih.gov/pubhealth/roc/roc13/index.html Thirteenth Report on Carcinogens] (2014).<ref name=roc/> The International Agency for Research on Cancer (IARC) has classified ''o''-toluidine as 'carcinogenic to humans (group 1)'.<ref>{{Cite book|url=http://monographs.iarc.fr/ENG/Monographs/vol99/|title=IARC Monographs|website=monographs.iarc.fr|access-date=2016-06-13}}</ref>

===Metabolism=== ''o''-Toluidine is absorbed through inhalation and dermal contact as well as from the gastrointestinal tract.<ref>{{cite journal|last1=Cheever |first1=K. |last2=Richards |first2=D. |last3=Plotnick |first3=H. |date=1980 |title=Metabolism of ''o''-, ''m''- and ''p''-toluidine in the adult male rat |journal=Toxicol. Appl. Pharmacol. |volume=56 |issue=3 |pages=361–369 |doi=10.1016/0041-008x(80)90069-1|pmid=7222020 }}</ref><ref name=npsolvents>{{cite book|first1=R. C. |last1=Hiles |first2=K. M. |last2=Abdo |chapter=5. ''ortho''-Toluidine |publisher=Elsevier |edition=2nd |title=Nitrogen and Phosphorus Solvents |editor-first=D. R. |editor-last=Buhler |editor2-first=D. J. |editor2-last=Reed |date=1990 |pages=202–207}}</ref><ref name=soneverettfiala>{{cite journal|last1=Son |first1=O. S. |last2=Everett |first2=D. W. |last3=Fiala |first3=E. S. |date=1980 |title=Metabolism of ''o''-[methyl-<sup>14</sup>C]toluidine in the F344 rat |journal=Xenobiotica |volume=10 |issue=7–8 |pages=457–468 |doi=10.3109/00498258009033781|pmid=7445517 }}</ref><ref>{{cite journal|last1=Brock |first1=W. J. |last2=Hundley |first2=S. G. |last3=Lieder |first3=P. H. |date=1990 |title=Hepatic macromolecular binding and tissue distribution of ''ortho''- and ''para''-toluidine in rats |journal=Toxicol. Lett. |volume=54 |issue=2–3 |pages=317–325 |doi=10.1016/0378-4274(90)90199-v|pmid=1701932}}</ref>

The metabolism of ''o''-toluidine involves many competing activating and deactivating pathways, including ''N''-acetylation, ''N''-oxidation, and ''N''-hydroxylation, and ring oxidation.<ref name=riedeletal>{{cite journal|last1=Riedel |first1=K. |last2=Scherer |first2=G. |last3=Engl |first3=J. |last4=Hagedorn |first4=H. W. |last5=Tricker |first5=A. R. |date=2006 |title=Determination of three carcinogenic aromatic amines in urine of smokers and nonsmokers |journal=J. Anal. Toxicol. |volume=30 |issue=3 |pages=187–195 |doi=10.1093/jat/30.3.187|pmid=16803653 |doi-access=free }}</ref> 4-Hydroxylation and ''N''-acetylation of toluidine are the major metabolic pathways in rats. The primary metabolism of ''o''-toluidine takes place in the endoplasmic reticulum. Exposure to ''o''-toluidine enhances the microsomal activity of aryl hydrocarbon hydroxylase (particularly in the kidney), NADPH-cytochrome c reductase and the content of cytochrome P-450. Cytochrome P450–mediated ''N''-hydroxylation to ''N''-hydroxy-''o''-toluidine, a carcinogenic metabolite, occurs in the liver. ''N''-Hydroxy-''o''-toluidine can be either metabolized to ''o''-nitrosotoluene or conjugated with glucuronic acid or sulfate and transported to the urinary bladder via the blood. Once in the bladder, ''N''-hydroxy-''o''-toluidine can be released from the conjugates in an acidic urine environment to either react directly with DNA or be bio-activated via sulfation or acetylation by cytosolic sulfotransferases or ''N''-acetyltransferases (presumably NAT1).<ref name=roc>{{cite web|title=''o''-Toluidine |work=Report on Carcinogens |edition=13th |url=https://ntp.niehs.nih.gov/sites/default/files/ntp/roc/content/profiles/toluidine.pdf |publisher=US National Institute of Health}}</ref> The postulated activated form (based on comparison with other aromatic amines), ''N''-acetoxy-''o''-toluidine, is a reactive ester that forms electrophilic arylnitrenium ions that can bind to DNA.<ref name=riedeletal/><ref>{{cite journal|last1=Kadlubar |first1=F. F. |last2=Badawi |first2=A. F. |date=1995 |title=Genetic susceptibility and carcinogen-DNA adduct formation in human urinary bladder carcinogenesis |journal=Toxicol. Lett. |volume=82–83 |pages=627–632 |doi=10.1016/0378-4274(95)03507-9|pmid=8597119 |url=https://zenodo.org/record/1258539 }}</ref><ref name=englishetal>{{cite journal|last1=English |first1=J. C. |last2=Bhat |first2=V. S. |last3=Ball |first3=G. L. |first4=McLellan |last4=C. J. |date=2012 |title=Establishing a total allowable concentration of o-toluidine in drinking water incorporating early lifestage exposure and susceptibility |journal=Regul. Toxicol. Pharmacol. |volume=64 |issue=2 |pages=269–284 |doi=10.1016/j.yrtph.2012.08.011|pmid=22940434 |url=https://zenodo.org/record/1259505 }}</ref> Other activation pathways (ring-oxidation pathways) for aromatic amines include peroxidase-catalyzed reactions that form reactive metabolites (quinone-imines formed from nonconjugated phenolic metabolites) in the bladder. These metabolites can produce reactive oxygen species, resulting in oxidative cellular damage and compensatory cell proliferation. Support for this mechanism comes from studies of oxidative DNA damage induced by o-toluidine metabolites in cultured human cells (HL-60), calf thymus DNA, and DNA fragments from key genes thought to be involved in carcinogenesis (the c-Ha-ras oncogene and the p53 tumor-suppressor gene).<ref name=ohkumaetal>{{cite journal|last1=Ohkuma |first1=Y. Y. |last2=Hiraku |first2=S. |last3=Oikawa |first3=S. |last4=Yamashita |first4=N. |last5=Murata |first5=M. |last6=Kawanishi |first6=S. |date=1999 |title=Distinct mechanisms of oxidative DNA damage by two metabolites of carcinogenic ''o''-toluidine |journal=Arch. Biochem. Biophys. |volume=372 |issue=1 |pages=97–106 |doi=10.1006/abbi.1999.1461 |pmid=10562421}}</ref><ref name=watanabeetal>{{cite journal|last1=Watanabe |first1=C |last2=Egami |first2=T |last3=Midorikawa |first3=K. |last4=Hiraku |first4=Y. |last5=Oikawa |first5=S. |last6=Kawanishi |first6=S |last7=Murata |first7=M. |date=2010 |title=DNA damage and estrogenic activity induced by the environmental pollutant 2-nitrotoluene and its metabolite |journal=Environ. Health Prev. Med. |volume=15 |issue=5 |pages=319–326 |doi=10.1007/s12199-010-0146-1|pmc=2921039 |pmid=21432561 |bibcode=2010EHPM...15..319W }}</ref> Also supporting this mechanism are observations of ''o''-toluidine-induced DNA damage (strand breaks) in cultured human bladder cells and bladder cells from rats and mice exposed ''in vivo'' to ''o''-toluidine.<ref>{{cite journal|last1=Robbiano |first1=L. |last2=Carrozzino |first2=R. |last3=Bacigalupo |first3=M. |last4=Corbu |first4=C. |last5=Brambilla |first5=G. |date=2002 |title=Correlation between induction of DNA fragmentation in urinary bladder cells from rats and humans and tissue-specific carcinogenic activity |journal=Toxicology |volume=179 |issue=1–2 |pages=115–128 |doi=10.1016/s0300-483x(02)00354-2|pmid=12204548 |bibcode=2002Toxgy.179..115R }}</ref><ref>{{cite journal|last1=Sekihashi |first1=K. |last2=Yamamoto |first2=A. |last3=Matsumura |first3=Y. |last4=Ueno |first4=S. |last5=Watanabe-Akanuma |first5=M. |last6=Kassie |first6=F |last7=Knasmuller |first7=S. |last8=Tsuda |first8=S. |last9=Sasaki |first9=Y. F. |date=2002 |title=Comparative investigation of multiple organs of mice and rats in the comet assay |journal=Mutat. Res. |volume=517 |issue=1–2 |pages=53–75 |doi=10.1016/s1383-5718(02)00034-7|pmid=12034309 |bibcode=2002MRGTE.517...53S }}</ref> thumbnail|Figure 1: Metabolism of ''o''-(methyl-<sup>14</sup>C)-toluidine hydrochloride in the rat.

===Excretion=== The main excretion pathway is through the urine where up to one-third of the administered compound was recovered unchanged. Major metabolites are 4-amino-''m''-cresol and to a lesser extent, ''N''-acetyl-4-amino-''m''-cresol,<ref name=soneverettfiala /> azoxytoluene, ''o''-nitrosotoluene, ''N''-acetyl-''o''-toluidine, ''N''-acetyl-''o''-aminobenzyl alcohol, anthranilic acid, ''N''-acetyl-anthranilic acid, 2-amino-''m''-cresol, ''p''-hydroxy-''o''-toluidine. Conjugates that were formed were predominated by sulfate conjugates over glucuronide conjugates by a ratio of 6:1.

===Related metabolic pathways=== Prilocaine, an amino amide-type local anesthetic, yields ''o''-toluidine when metabolized by carboxylesterase enzymes.<ref>{{cite journal|title=Prilocaine- and Lidocaine-Induced Methemoglobinemia Is Caused by Human Carboxylesterase-, CYP2E1-, and CYP3A4-Mediated Metabolic Activation|author=Ryota Higuchi |author2=Tatsuki Fukami |author3=Miki Nakajima |author4=Tsuyoshi Yokoi |journal=Drug Metab. Dispos.|year=2013|volume=41|issue=6 |pages=1220–1230 |doi=10.1124/dmd.113.051714|pmid=23530020 |s2cid=9741909 }}</ref> Large prilocaine doses can cause methemoglobinemia due to oxidation of hemoglobin by ''o''-toluidine.<ref>{{cite journal|title=Prilocaine-Induced Methemoglobinemia|author=Medetalibeyoğlu A. |author2=Koç E.S. |author3=Beyaz O. |author4=Edizer A. |journal=Case Rep. Acute Med.|year=2020|volume=3|issue=2 |page=25-28|doi=10.1159/000508403|doi-access=free}}</ref> ==Drugs List== {{Confusing|section|date=January 2025}} #Aptocaine #Asulacrine #Dazepinil #Methaqualone #Metolazone #Prilocaine #Quatacaine (Tanacaine)

==References== {{reflist|30em}}

{{DEFAULTSORT:Toluidine, o-}} Category:2-Aminophenyl compounds Category:2-Tolyl compounds Category:IARC Group 1 carcinogens